Download full-text


Available from: John Camm, Jun 04, 2014
88 Reads
  • Source
    • "Paroxysmal AF is defined as self-terminating episode, usually within 48 h, and may continue for up to 7 days [7]. Lone AF was defined in patients who were b60 years old; without structural heart disease based "
    International journal of cardiology 03/2015; 185. DOI:10.1016/j.ijcard.2015.03.091 · 4.04 Impact Factor
  • Source
    • "Special attention should be paid to the group of Dr. Spodick from USA that investigated several aspects of IAB and specifically its relation to stroke [6] [26] and to the electromechanical dysfunction of the left atrium associated to IAB [4] [5] [6]. Daubert's group from France, studied different aspects of atrial pacing associated with the presence of advanced IAB [24]. Garcia-Cosio's group from Spain performed interesting studies using intracardiac mapping, demonstrating the retrograde activation of the left atrium in these patients [28] [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Interatrial blocks (IABs) are well described and accepted in the scientific community. In the last four decades major discoveries were made including its physiopathology, ECG presentation, classification and association with atrial tachyarrhythmias (advanced IAB). This article will briefly review the state of the art on the understanding of advanced IAB as an electrical substrate for atrial tachyarrhythmias as well as the future directions. Copyright © 2014 Elsevier Inc. All rights reserved.
    Journal of Electrocardiology 01/2015; 48(2). DOI:10.1016/j.jelectrocard.2014.12.015 · 1.36 Impact Factor
  • Source
    • "This was a prospective single-center study that included 867 consecutive patients with AF who referred to the Atherothrombosis Center of the Department of Internal Medicine and Medical Specialties of " Sapienza " University of Rome from February 2008 to December 2013. All patients were treated with vitamin K antagonists (VKAs, warfarin/acenocumarol) initially according to CHADS 2 score, and afterwards patients were re-classified according to the CHA 2 DS 2 -VASc score [21]. Anticoagulation therapy was monitored by the International Normalized Ratio, in a therapeutic range of 2.0–3.0. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Some evidences suggest that the use of digoxin may be harmful inatrial fibrillation (AF) patients. The aim of the study was to investigate in a “real world” of AF patients receiving vitamin K antagonists (VKAs), the relationship between digoxin use and mortality.Methods Prospective single-center observational study including 815 consecutive non-valvular AF patients treated with VKAs. Total mortality was the primary outcome of the study. We also performed a sub-analysis considering only cardiovascular (CV) deaths. Time in therapeutic range (TTR) was used for anticoagulation quality.ResultsMedian follow-up was 33.2 months (2460 person-years); 171 (21.0%) patients were taking digoxin. Compared to those without, patients on digoxin were older (p = 0.007), with a clinical history of HF (p < 0.001) and at higher risk of thromboembolic events (p < 0.001). No difference in TTR between the two groups was registered (p = 0.598). During the follow-up, 85 deaths occurred: 47 CV and 38 non-CV deaths; 35 deaths occurred in digoxin users (20.6%). A significant increased rate of total mortality was observed in digoxin-treated patients (p < 0.001). Multivariable analysis showed that digoxin was associated with total mortality (hazard ratio [HR]: 2.224, p < 0.001) and CV death (HR: 4.686, p < 0.001). A propensity score-matched analysis confirmed that digoxin was associated with total mortality (HR: 2.073, p = 0.0263) and CV death (HR: 4.043, p = 0.004).Conclusions In AF patients on good anticoagulation control with VKAs, digoxin use was associated with a higher rate of total and CV mortality.
    International Journal of Cardiology 11/2014; 180. DOI:10.1016/j.ijcard.2014.11.112 · 4.04 Impact Factor
Show more